|
- A SIP® modified novel Glucagon-like Peptide-2 (GLP-2) analogue with enhanced stability and efficacy, exerting trophic, protective effects on the intestinal mucosa
- In Phase lb development for Chemotherapy-Induced Diarrhoea (CID), a condition that may require hospitalisation and in the most severe cases may result in death
- Potentially a first-in-class cancer supportive drug
- A 39 amino acids polypeptide: H-HGEGSFSSELSTILDALAARDFIAWLIATKITDKKKKKK-NH2
Originator: Zealand Pharma A/S - Denmark
|
|
